Case Studies in HIV Prevention among Adolescents and Young Adults

HIV is a preventable disease. As clinicians we have the tools to protect our patients, and as members of the public health community, we have the tools to end the HIV epidemic. In 2019, the US announced the End the HIV Epidemic (EHE) initiative. EHE’s goals include reducing new HIV infections in the United States by 75% by 2025 and by 90% by 2030 and advancing health equity by scaling up HIV prevention and treatment strategies. The pillars of the plan are:

• Diagnose all people with HIV as early as possible
• Treat people with HIV rapidly and effectively to reach sustained viral suppression.
• Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs).
• Respond quickly to potential HIV outbreaks to get vital prevention and treatment services to people who need them.

Preventing HIV in our own communities requires proactive, interdisciplinary care based on these time-proven methods. Using a practical case-based approach, this webinar will review the basic principles of HIV prevention including U=U, safer sex, and PrEP, and will discuss the essential need for teamwork in providing HIV prevention as an integrated part of sexual healthcare for adolescents and young adults.

What You Can Expect:

1. Practical Application of the Science: Our expert faculty educators will guide you through this engaging and informative program, and offer suggestions on how you can apply the latest science to patient care.
2. Patient-Centered Care: Learn from faculty who are directly involved in patient care about strategies for providing compassionate care that addresses individuals’ unique needs and challenges.
3. Team Focused: Explore how HIV clinicians from multiple professions are collaborating to optimize patient care.

• Review rationales for increasing youth access to PrEP, the concept of risk within social networks, and how PrEP eligibility criteria pertain to youth
• Comfortably explain and offer Pre-Exposure Prophylaxis (PrEP) to adolescents and young adults.
• Identify opportunities for interdisciplinary collaborations that create clinical environments which help connect youth to HIV prevention care.
• Describe testing guidelines and lead in periods for long-acting PrEP injectables as well as how to explain and counsel effectively about “the tail.”

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NPs and Nurses:

American Academy of CME, Inc., designates this educational activity for 1.25 ANCC contact hours
(1.0 Pharmacotherapeutic Contact Hours).

California
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.25 contact hours.

Physician Assistants

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until December 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other members of the care team will receive a certificate of participation.

Support

Support for this activity has been made possible through an educational grant from Gilead Sciences.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Educator/Planner Disclosures

Maria Teresa Timoney RN, CNM, NP: No relevant financial relationships to disclose
Roberta Laguerre-Frederique, MD, AAHIVS: Advisory Board/Consultant-ViiV Healthcare, Pfizer

Planning Team:

Jonathan Colasanti, MD; Courtney Fletcher, PharmD; Jose Gutierrez, PhD, FNP-BC; Asa E. Radix, MD, PhD, MPH; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Daiquiri Y. Robinson, MEd: No relevant financial relationships to disclose.
Roger Bedimo, MD, MS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Merck, Theratechnologies, Janssen, Shionogi; Grant/Research Support – Merck
William R. Short, MD, MPH: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences; Grant/Research Support – Gilead Sciences, Janssen*
H. Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Sarah Smith, MHS, PA-C, AAHIVS: Advisory Board/Consultant – ViiV Healthcare, Gilead Sciences, Janssen, Merck; Speakers Bureau – ViiV Healthcare, Gilead Sciences, Janssen, Merck
*Relationship has ended.
This activity does not include information about off-label uses of approved agents and/or investigational agents.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy/ACTHIV® Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.